A recent study by Chan and colleagues found that CR-1-31-B treatment reduced the viability of pancreatic ductal adenocarcinoma (PDAC) organoids and suppressed tumor growth in a rodent PDAC model [34]. This evidence concerns the gene CR1 and pancreatic ductal adenocarcinoma.